Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation

Diosbulbin B (DBB), the major component isolated from herbal medicine Dioscorea bulbifera L. (DBL), can trigger severe hepatotoxicity. The previous studies demonstrated that DBB-induced hepatotoxicity is closely relevant to the bioactivation mediated by CYP3A4 and subsequent generation of adducts wi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Toxicology and applied pharmacology 2024-11, Vol.492, p.117116, Article 117116
Hauptverfasser: Lin, Dongju, Wang, Shuo, Yang, Bufan, Li, Guangyao
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 117116
container_title Toxicology and applied pharmacology
container_volume 492
creator Lin, Dongju
Wang, Shuo
Yang, Bufan
Li, Guangyao
description Diosbulbin B (DBB), the major component isolated from herbal medicine Dioscorea bulbifera L. (DBL), can trigger severe hepatotoxicity. The previous studies demonstrated that DBB-induced hepatotoxicity is closely relevant to the bioactivation mediated by CYP3A4 and subsequent generation of adducts with cellular proteins. Schisandrol B (SchB), the primary lignan ingredient in herbal medicine Schisandra chinensis (SC), is able to inhibit CYP3A activity. The objective of this study is to investigate the protective effect of SchB against hepatotoxicity induced by DBB and to explore the underlying mechanism. Biochemical and histopathological analysis demonstrated that SchB exerted dose-dependent protective effect against DBB-induced hepatotoxicity. In vitro metabolism assay showed that the formation of pyrrole-glutathione (GSH) conjugates of DBB was inhibited by SchB in a concentration dependent manner, suggesting SchB inhibited the bioactivation of DBB in vitro. Pharmacokinetic studies demonstrated that SchB enhanced Cmax and AUCs of DBB in mouse blood and liver, resulting in accelerating the accumulation of DBB in the circulation. In addition, pretreatment with SchB alleviated DBB-induced hepatic GSH depletion, obviously facilitated the excretion of DBB in urine, and reduced the urinary excretion of DBB-GSH conjugates, indicating that SchB affected absorption, distribution, metabolism, and excretion (ADME) of DBB by inhibiting the bioactivation of DBB in vivo. In conclusion, our findings demonstrated the amelioration of SchB against DBB-induced hepatotoxicity was correlated with the inhibition of CYP3A4-mediated bioactivation of DBB. Thus, the findings indicated that SchB may serve as a potential candidate drug for the treatment of DBB intoxication. •SchB protected against DBB-induced hepatotoxicity in a dose dependent manner.•SchB inhibited the bioactivation of DBB in vitro and in vivo.•The ameliorative effect of SchB against DBB-induced hepatotoxicity was associated with inhibiting the bioactivation of DBB.
doi_str_mv 10.1016/j.taap.2024.117116
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3112526795</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041008X24003156</els_id><sourcerecordid>3112526795</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-c1901b8ae0f05fb452794bf4f2d017d2255460423d54a147f51bb1310b9c11d63</originalsourceid><addsrcrecordid>eNp9kEGP0zAQhS0EYrsLf4AD8pFLyoztJI3EpVtgQVoJJECCk2U79naqNC6xU7EH_juuunDkNJdv3tP7GHuBsETA5vVumY05LAUItURsEZtHbIHQNRVIKR-zBYDCCmD1_YJdprQDgE4pfMouZCfrtlnBgv1e7_1AcTKZjp77ELzLPAb-xW0pmbGf4sCvubkzNKbM31JMdh4sjfy6orGfne_51h9Mjjn-Ikf5nh_JcBq3ZCnTeMc3Pz7Ltar2vieTC20pGlfKSmEcn7EnwQzJP3-4V-zb-3dfNx-q2083Hzfr28oJ2ebKYQdoV8ZDgDpYVYu2UzaoIHrAtheirlUDSsi-VgZVG2q0FiWC7Rxi38gr9uqce5jiz9mnrPeUnB8GM_o4Jy0RRS2atqsLKs6om2JKkw_6MNHeTPcaQZ-0650-adcn7fqsvTy9fMifbVn67-Wv5wK8OQO-rDySn3Ry5Meij6ZiXPeR_pf_B2g1lCc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3112526795</pqid></control><display><type>article</type><title>Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Lin, Dongju ; Wang, Shuo ; Yang, Bufan ; Li, Guangyao</creator><creatorcontrib>Lin, Dongju ; Wang, Shuo ; Yang, Bufan ; Li, Guangyao</creatorcontrib><description>Diosbulbin B (DBB), the major component isolated from herbal medicine Dioscorea bulbifera L. (DBL), can trigger severe hepatotoxicity. The previous studies demonstrated that DBB-induced hepatotoxicity is closely relevant to the bioactivation mediated by CYP3A4 and subsequent generation of adducts with cellular proteins. Schisandrol B (SchB), the primary lignan ingredient in herbal medicine Schisandra chinensis (SC), is able to inhibit CYP3A activity. The objective of this study is to investigate the protective effect of SchB against hepatotoxicity induced by DBB and to explore the underlying mechanism. Biochemical and histopathological analysis demonstrated that SchB exerted dose-dependent protective effect against DBB-induced hepatotoxicity. In vitro metabolism assay showed that the formation of pyrrole-glutathione (GSH) conjugates of DBB was inhibited by SchB in a concentration dependent manner, suggesting SchB inhibited the bioactivation of DBB in vitro. Pharmacokinetic studies demonstrated that SchB enhanced Cmax and AUCs of DBB in mouse blood and liver, resulting in accelerating the accumulation of DBB in the circulation. In addition, pretreatment with SchB alleviated DBB-induced hepatic GSH depletion, obviously facilitated the excretion of DBB in urine, and reduced the urinary excretion of DBB-GSH conjugates, indicating that SchB affected absorption, distribution, metabolism, and excretion (ADME) of DBB by inhibiting the bioactivation of DBB in vivo. In conclusion, our findings demonstrated the amelioration of SchB against DBB-induced hepatotoxicity was correlated with the inhibition of CYP3A4-mediated bioactivation of DBB. Thus, the findings indicated that SchB may serve as a potential candidate drug for the treatment of DBB intoxication. •SchB protected against DBB-induced hepatotoxicity in a dose dependent manner.•SchB inhibited the bioactivation of DBB in vitro and in vivo.•The ameliorative effect of SchB against DBB-induced hepatotoxicity was associated with inhibiting the bioactivation of DBB.</description><identifier>ISSN: 0041-008X</identifier><identifier>ISSN: 1096-0333</identifier><identifier>EISSN: 1096-0333</identifier><identifier>DOI: 10.1016/j.taap.2024.117116</identifier><identifier>PMID: 39357680</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Activation, Metabolic ; Animals ; Bioactivation ; Chemical and Drug Induced Liver Injury - etiology ; Chemical and Drug Induced Liver Injury - prevention &amp; control ; Cyclooctanes - pharmacology ; Cyclooctanes - toxicity ; Cytochrome P-450 CYP3A - metabolism ; Cytochrome P-450 CYP3A Inhibitors - pharmacology ; Diosbulbin B ; Dioxoles ; Dose-Response Relationship, Drug ; Glutathione - metabolism ; Hepatotoxicity ; Heterocyclic Compounds, 4 or More Rings ; Humans ; Lignans - pharmacokinetics ; Lignans - pharmacology ; Liver - drug effects ; Liver - metabolism ; Liver - pathology ; Male ; Mice ; Microsomes, Liver - drug effects ; Microsomes, Liver - metabolism ; Polycyclic Compounds - pharmacology ; Polycyclic Compounds - toxicity ; Schisandrol B</subject><ispartof>Toxicology and applied pharmacology, 2024-11, Vol.492, p.117116, Article 117116</ispartof><rights>2024 Elsevier Inc.</rights><rights>Copyright © 2024 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-c1901b8ae0f05fb452794bf4f2d017d2255460423d54a147f51bb1310b9c11d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0041008X24003156$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39357680$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Dongju</creatorcontrib><creatorcontrib>Wang, Shuo</creatorcontrib><creatorcontrib>Yang, Bufan</creatorcontrib><creatorcontrib>Li, Guangyao</creatorcontrib><title>Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation</title><title>Toxicology and applied pharmacology</title><addtitle>Toxicol Appl Pharmacol</addtitle><description>Diosbulbin B (DBB), the major component isolated from herbal medicine Dioscorea bulbifera L. (DBL), can trigger severe hepatotoxicity. The previous studies demonstrated that DBB-induced hepatotoxicity is closely relevant to the bioactivation mediated by CYP3A4 and subsequent generation of adducts with cellular proteins. Schisandrol B (SchB), the primary lignan ingredient in herbal medicine Schisandra chinensis (SC), is able to inhibit CYP3A activity. The objective of this study is to investigate the protective effect of SchB against hepatotoxicity induced by DBB and to explore the underlying mechanism. Biochemical and histopathological analysis demonstrated that SchB exerted dose-dependent protective effect against DBB-induced hepatotoxicity. In vitro metabolism assay showed that the formation of pyrrole-glutathione (GSH) conjugates of DBB was inhibited by SchB in a concentration dependent manner, suggesting SchB inhibited the bioactivation of DBB in vitro. Pharmacokinetic studies demonstrated that SchB enhanced Cmax and AUCs of DBB in mouse blood and liver, resulting in accelerating the accumulation of DBB in the circulation. In addition, pretreatment with SchB alleviated DBB-induced hepatic GSH depletion, obviously facilitated the excretion of DBB in urine, and reduced the urinary excretion of DBB-GSH conjugates, indicating that SchB affected absorption, distribution, metabolism, and excretion (ADME) of DBB by inhibiting the bioactivation of DBB in vivo. In conclusion, our findings demonstrated the amelioration of SchB against DBB-induced hepatotoxicity was correlated with the inhibition of CYP3A4-mediated bioactivation of DBB. Thus, the findings indicated that SchB may serve as a potential candidate drug for the treatment of DBB intoxication. •SchB protected against DBB-induced hepatotoxicity in a dose dependent manner.•SchB inhibited the bioactivation of DBB in vitro and in vivo.•The ameliorative effect of SchB against DBB-induced hepatotoxicity was associated with inhibiting the bioactivation of DBB.</description><subject>Activation, Metabolic</subject><subject>Animals</subject><subject>Bioactivation</subject><subject>Chemical and Drug Induced Liver Injury - etiology</subject><subject>Chemical and Drug Induced Liver Injury - prevention &amp; control</subject><subject>Cyclooctanes - pharmacology</subject><subject>Cyclooctanes - toxicity</subject><subject>Cytochrome P-450 CYP3A - metabolism</subject><subject>Cytochrome P-450 CYP3A Inhibitors - pharmacology</subject><subject>Diosbulbin B</subject><subject>Dioxoles</subject><subject>Dose-Response Relationship, Drug</subject><subject>Glutathione - metabolism</subject><subject>Hepatotoxicity</subject><subject>Heterocyclic Compounds, 4 or More Rings</subject><subject>Humans</subject><subject>Lignans - pharmacokinetics</subject><subject>Lignans - pharmacology</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>Liver - pathology</subject><subject>Male</subject><subject>Mice</subject><subject>Microsomes, Liver - drug effects</subject><subject>Microsomes, Liver - metabolism</subject><subject>Polycyclic Compounds - pharmacology</subject><subject>Polycyclic Compounds - toxicity</subject><subject>Schisandrol B</subject><issn>0041-008X</issn><issn>1096-0333</issn><issn>1096-0333</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEGP0zAQhS0EYrsLf4AD8pFLyoztJI3EpVtgQVoJJECCk2U79naqNC6xU7EH_juuunDkNJdv3tP7GHuBsETA5vVumY05LAUItURsEZtHbIHQNRVIKR-zBYDCCmD1_YJdprQDgE4pfMouZCfrtlnBgv1e7_1AcTKZjp77ELzLPAb-xW0pmbGf4sCvubkzNKbM31JMdh4sjfy6orGfne_51h9Mjjn-Ikf5nh_JcBq3ZCnTeMc3Pz7Ltar2vieTC20pGlfKSmEcn7EnwQzJP3-4V-zb-3dfNx-q2083Hzfr28oJ2ebKYQdoV8ZDgDpYVYu2UzaoIHrAtheirlUDSsi-VgZVG2q0FiWC7Rxi38gr9uqce5jiz9mnrPeUnB8GM_o4Jy0RRS2atqsLKs6om2JKkw_6MNHeTPcaQZ-0650-adcn7fqsvTy9fMifbVn67-Wv5wK8OQO-rDySn3Ry5Meij6ZiXPeR_pf_B2g1lCc</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Lin, Dongju</creator><creator>Wang, Shuo</creator><creator>Yang, Bufan</creator><creator>Li, Guangyao</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202411</creationdate><title>Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation</title><author>Lin, Dongju ; Wang, Shuo ; Yang, Bufan ; Li, Guangyao</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-c1901b8ae0f05fb452794bf4f2d017d2255460423d54a147f51bb1310b9c11d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Activation, Metabolic</topic><topic>Animals</topic><topic>Bioactivation</topic><topic>Chemical and Drug Induced Liver Injury - etiology</topic><topic>Chemical and Drug Induced Liver Injury - prevention &amp; control</topic><topic>Cyclooctanes - pharmacology</topic><topic>Cyclooctanes - toxicity</topic><topic>Cytochrome P-450 CYP3A - metabolism</topic><topic>Cytochrome P-450 CYP3A Inhibitors - pharmacology</topic><topic>Diosbulbin B</topic><topic>Dioxoles</topic><topic>Dose-Response Relationship, Drug</topic><topic>Glutathione - metabolism</topic><topic>Hepatotoxicity</topic><topic>Heterocyclic Compounds, 4 or More Rings</topic><topic>Humans</topic><topic>Lignans - pharmacokinetics</topic><topic>Lignans - pharmacology</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>Liver - pathology</topic><topic>Male</topic><topic>Mice</topic><topic>Microsomes, Liver - drug effects</topic><topic>Microsomes, Liver - metabolism</topic><topic>Polycyclic Compounds - pharmacology</topic><topic>Polycyclic Compounds - toxicity</topic><topic>Schisandrol B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Dongju</creatorcontrib><creatorcontrib>Wang, Shuo</creatorcontrib><creatorcontrib>Yang, Bufan</creatorcontrib><creatorcontrib>Li, Guangyao</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Toxicology and applied pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Dongju</au><au>Wang, Shuo</au><au>Yang, Bufan</au><au>Li, Guangyao</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation</atitle><jtitle>Toxicology and applied pharmacology</jtitle><addtitle>Toxicol Appl Pharmacol</addtitle><date>2024-11</date><risdate>2024</risdate><volume>492</volume><spage>117116</spage><pages>117116-</pages><artnum>117116</artnum><issn>0041-008X</issn><issn>1096-0333</issn><eissn>1096-0333</eissn><abstract>Diosbulbin B (DBB), the major component isolated from herbal medicine Dioscorea bulbifera L. (DBL), can trigger severe hepatotoxicity. The previous studies demonstrated that DBB-induced hepatotoxicity is closely relevant to the bioactivation mediated by CYP3A4 and subsequent generation of adducts with cellular proteins. Schisandrol B (SchB), the primary lignan ingredient in herbal medicine Schisandra chinensis (SC), is able to inhibit CYP3A activity. The objective of this study is to investigate the protective effect of SchB against hepatotoxicity induced by DBB and to explore the underlying mechanism. Biochemical and histopathological analysis demonstrated that SchB exerted dose-dependent protective effect against DBB-induced hepatotoxicity. In vitro metabolism assay showed that the formation of pyrrole-glutathione (GSH) conjugates of DBB was inhibited by SchB in a concentration dependent manner, suggesting SchB inhibited the bioactivation of DBB in vitro. Pharmacokinetic studies demonstrated that SchB enhanced Cmax and AUCs of DBB in mouse blood and liver, resulting in accelerating the accumulation of DBB in the circulation. In addition, pretreatment with SchB alleviated DBB-induced hepatic GSH depletion, obviously facilitated the excretion of DBB in urine, and reduced the urinary excretion of DBB-GSH conjugates, indicating that SchB affected absorption, distribution, metabolism, and excretion (ADME) of DBB by inhibiting the bioactivation of DBB in vivo. In conclusion, our findings demonstrated the amelioration of SchB against DBB-induced hepatotoxicity was correlated with the inhibition of CYP3A4-mediated bioactivation of DBB. Thus, the findings indicated that SchB may serve as a potential candidate drug for the treatment of DBB intoxication. •SchB protected against DBB-induced hepatotoxicity in a dose dependent manner.•SchB inhibited the bioactivation of DBB in vitro and in vivo.•The ameliorative effect of SchB against DBB-induced hepatotoxicity was associated with inhibiting the bioactivation of DBB.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39357680</pmid><doi>10.1016/j.taap.2024.117116</doi></addata></record>
fulltext fulltext
identifier ISSN: 0041-008X
ispartof Toxicology and applied pharmacology, 2024-11, Vol.492, p.117116, Article 117116
issn 0041-008X
1096-0333
1096-0333
language eng
recordid cdi_proquest_miscellaneous_3112526795
source MEDLINE; Elsevier ScienceDirect Journals
subjects Activation, Metabolic
Animals
Bioactivation
Chemical and Drug Induced Liver Injury - etiology
Chemical and Drug Induced Liver Injury - prevention & control
Cyclooctanes - pharmacology
Cyclooctanes - toxicity
Cytochrome P-450 CYP3A - metabolism
Cytochrome P-450 CYP3A Inhibitors - pharmacology
Diosbulbin B
Dioxoles
Dose-Response Relationship, Drug
Glutathione - metabolism
Hepatotoxicity
Heterocyclic Compounds, 4 or More Rings
Humans
Lignans - pharmacokinetics
Lignans - pharmacology
Liver - drug effects
Liver - metabolism
Liver - pathology
Male
Mice
Microsomes, Liver - drug effects
Microsomes, Liver - metabolism
Polycyclic Compounds - pharmacology
Polycyclic Compounds - toxicity
Schisandrol B
title Ameliorative effect of Schisandrol B against Diosbulbin B-induced hepatotoxicity via inhibiting CYP3A4-mediated bioactivation
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T22%3A46%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ameliorative%20effect%20of%20Schisandrol%20B%20against%20Diosbulbin%20B-induced%20hepatotoxicity%20via%20inhibiting%20CYP3A4-mediated%20bioactivation&rft.jtitle=Toxicology%20and%20applied%20pharmacology&rft.au=Lin,%20Dongju&rft.date=2024-11&rft.volume=492&rft.spage=117116&rft.pages=117116-&rft.artnum=117116&rft.issn=0041-008X&rft.eissn=1096-0333&rft_id=info:doi/10.1016/j.taap.2024.117116&rft_dat=%3Cproquest_cross%3E3112526795%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3112526795&rft_id=info:pmid/39357680&rft_els_id=S0041008X24003156&rfr_iscdi=true